We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ALBI:EURONEXT PARISGascogne Analysis

Data as of 2026-05-23 - not real-time

€2.46

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Technical outlook: The stock is trading below its short‑term and mid‑term moving averages and under the long‑term trend line, signaling bearish momentum. The relative strength index hovers around the neutral zone, while the MACD shows a marginal bullish tilt that has not yet translated into price strength. Volume has been on a downtrend, and recent price action is confined between a clear support zone and a modest resistance ceiling, suggesting limited upside in the near term. Volatility has been elevated, beta remains low, and the historical drawdown has been pronounced, underscoring heightened price sensitivity.
Fundamental perspective: Revenue is expanding at a solid pace, yet margins remain negative and profitability is elusive, compounded by a heavy debt load and modest cash reserves. Valuation metrics point to a sizeable gap between the current market price and the discounted cash‑flow derived fair value, delivering a considerable upside potential. The price‑to‑earnings ratio is far below the industry average, and the company does not pay a dividend, indicating that any return must stem from capital appreciation. Overall, the stock appears undervalued but carries significant execution risk, making a cautious stance prudent.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price below short‑term moving averages
  • declining trading volume
  • bearish trend despite a faint MACD bullish hint

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • substantial upside to fair‑value estimate
  • robust revenue growth trajectory
  • potential for operating cash‑flow improvement

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • persistent undervaluation relative to intrinsic worth
  • opportunity for strategic restructuring to lift margins
  • low beta suggesting limited market‑wide volatility over time

Key Metrics & Analysis

Financial Health

Revenue Growth22.80%
Profit Margin-4.24%
P/E Ratio7.7
ROE-60.90%
ROA-4.48%
Debt/Equity322.71
P/B Ratio2.0
Op. Cash Flow€1.9M
Free Cash Flow€-256150
Industry P/E17.0

Technical Analysis

TrendBearish
RSI49.6
Support€2.30
Resistance€2.59
MA 20€2.44
MA 50€2.46
MA 200€2.74
MACDBullish
VolumeDecreasing
Fear & Greed Index91.61

Valuation

Fair Value€3.99
Target Price€3.35
Upside/Downside36.18%
GradeUndervalued
TypeBlend

Risk Assessment

Beta0.53
Volatility29.20%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.